Chandan Healthcare Limited Q2 revenue rises 45%, adjusted profit 46%
Key highlights
- Chandan Healthcare's Q2 FY27 revenue from operations rose 45.04% year on year to Rs 57.94 crore.
- Chandan Healthcare's Q2 FY27 EBITDA increased 54.79% to Rs 22.12 crore and margin reached 37.26%.
- Chandan Healthcare said adjusted Q2 FY27 profit was about Rs 8.3 crore, excluding a Rs 10.23 crore post-tax pharmacy-sale gain.
- Chandan Healthcare added 410 franchise centres in Q2 FY27, taking the September 30, 2026 total to 685.
powered by IRIS

Chandan Healthcare Limited reported Q2 FY27 revenue from operations of Rs 57.94 crore, up 45.04% year on year, while profit after tax excluding a Rs 10.23 crore post-tax pharmacy-sale gain rose about 46% to Rs 8.3 crore. The standalone figures exclude the divested pharmacy business and measure diagnostics operations on a like-for-like basis.
Know Chandan Healthcare inside out
Results, valuation, peers and who's buying, in one view.
How did Chandan Healthcare perform in Q2 FY27?
Chandan Healthcare increased Q2 FY27 revenue from operations by 45.04% year on year to Rs 57.94 crore, while total income rose 44.78% to Rs 59.36 crore. Chandan Pharmacy Limited ceased to be a subsidiary during the quarter, so management presented both current and prior-year numbers on a standalone basis.
Earnings before interest, tax, depreciation and amortisation, or EBITDA, rose 54.79% to Rs 22.12 crore in the quarter ended September 30, 2026. EBITDA margin increased 241 basis points, where one basis point equals one-hundredth of a percentage point, to 37.26%. Compared with the quarter ended June 30, 2026, total income grew 19.3% and EBITDA rose 21.57%, with margin increasing 69 basis points.
For H1 FY27, revenue from operations reached Rs 106.61 crore, up 41.16%, and total income rose 40.56% to Rs 109.12 crore. H1 EBITDA increased 66.52% to Rs 40.31 crore, while management said the EBITDA margin improved by around 576 basis points, a faster operating-earnings increase than the revenue increase.
Why was Chandan Healthcare's reported profit higher than adjusted profit?
Chandan Healthcare reported Q2 FY27 profit after tax of Rs 18.61 crore, with a 31.35% margin, because the result included a Rs 10.23 crore post-tax gain on the sale of Chandan Pharmacy Limited shares. The company completed the divestment of its entire 53.56% stake on September 1, 2026, for approximately Rs 16.77 crore.
Excluding that one-time gain, management put Q2 FY27 profit after tax at about Rs 8.3 crore, compared with Rs 5.74 crore a year earlier. That represents growth of around 46%, while the adjusted margin was about 14.1%, compared with 14% in the prior-year quarter. The reported and adjusted figures therefore reflect different measures of performance.
The distinction also affects H1 FY27. Reported profit after tax was Rs 25.37 crore, up 256.72% year on year, whereas profit excluding the pharmacy-sale gain was about Rs 15.14 crore, up 113% from Rs 7.11 crore. The reported H1 margin was 23.25%.
Which segments drove Chandan Healthcare's Q2 growth?
Chandan Healthcare's business-to-business, or B2B, segment was the fastest-growing stated revenue stream in Q2 FY27, increasing 106.5% year on year and contributing 36.7% of revenue. Business-to-consumer, or B2C, accounted for 34.5% and grew 23.8%, while business-to-government, or B2G, made up 28.8% and rose 17.2%.
B2B's 36.7% contribution placed it ahead of B2C's 34.5% share in Q2 FY27. Pathology represented around 75% of quarterly revenue and radiology the remaining 25%. Management also said the five-year exclusive arrangement with Jeena Sikho hospitals and clinics had crossed monthly revenue of Rs 1.5 crore.
The company said its Chandan 24x7 application had more than 3,00,050 members as of September 30, 2026, with 5,000 to 10,000 additions a month. Its owned network comprised 25 comprehensive diagnostic centres, 19 diagnostic centres, 25 standalone laboratories, 16 radiology centres and two central laboratories.
Got a follow-up? Ask IRIS
How is Chandan Healthcare replacing NHM business?
Chandan Healthcare plans to replace National Health Mission, or NHM, business through franchise expansion and acquisitions rather than contract renewals. Management said NHM accounted for 22% to 23%, while total government business was about 28%. It had closed 100 of 350 NHM collection points in Uttarakhand and said it would not apply for the next tender expected within two or three months.
The franchise network added 410 centres during Q2 FY27, taking the count to 685 on September 30, 2026. Management said the number had exceeded 930 by the call date and that about 80% of the network was in Uttar Pradesh. It targets 1,500 franchise centres by the end of FY27 and more than 4,000 by the end of FY28.
Management said a franchise that has operated for about six months can generate more than Rs 2 lakh in monthly business, of which Chandan Healthcare receives roughly Rs 1 lakh. It described the franchise model as requiring no capital from the company because partners bear local and sample-transfer costs, and said it added 280 franchises in October.
What expansion plans could affect Chandan Healthcare's results?
Chandan Healthcare expects to open 11 comprehensive diagnostic centres and six diagnostic centres within three to four months of the call. Management said about 80% of the investment in the comprehensive centres had already been made. It also plans to open a central reference laboratory in Delhi within six months, adding to existing central laboratories in Lucknow and Haldwani.
The company acquired two Ansh Diagnostic and Healthcare units in Ghaziabad on September 25, 2026, adding pathology, radiology, computed tomography and magnetic resonance imaging services. Management also outlined planned positron emission tomography scan centres in Kanpur, Haldwani, Jodhpur, Bhopal, Raipur and Gorakhpur, with Gorakhpur expected to start within two months.
Management expects 12 Punjab public-private partnership radiology centres to begin contributing progressively from Q4 FY27. It said 11 centres had been handed over and were undergoing machine installation. For FY28, management outlined about Rs 100 crore of investment in 12 comprehensive centres and more than 50 general laboratories, while a standalone laboratory was said to cost Rs 50 lakh to Rs 75 lakh.
Conclusion
Chandan Healthcare's quarter shows that the underlying diagnostics business grew independently of the pharmacy divestment: revenue expanded 45.04%, EBITDA rose 54.79%, and management calculated adjusted profit growth of around 46%. B2B revenue grew 106.5%, while pathology remained the larger service vertical at about 75% of Q2 revenue.
The next results will test whether franchises, acquisitions and new centres can offset the NHM withdrawal. Management expects Punjab radiology projects to affect results from Q4 FY27, plans 1,500 franchise centres by FY27-end, and expects 11 comprehensive diagnostic centres and six diagnostic centres to open within three to four months.


